Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

• Status: Completed
• Trial end date: 2019-03-14
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Deoxyglucose; Diphosphonates; Fluorides; Fluorodeoxyglucose F18; Listerine; Methylene diphosphonate; Sodium Fluoride; Technetium Tc 99m Medronate

Criteria

All patients were enrolled after receiving a regular medical care bone scan using the radiolabel 99mTc-methyl diphosphonate (t99-MDP).

INCLUSION CRITERIA

• ≥ 18 years old at the time of the drug administration

• ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen (PSA) > 10 micrograms/L OR recurrent breast or prostate cancer

• Capable of complying with study procedures

• Able to remain still for duration of imaging procedure (about one hour)

• Written informed consent

EXCLUSION CRITERIA

• Pregnant or nursing

• Metallic implants that contraindicate MRI

• Renal function impairment that contraindicates MRI